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ABSTRACT
Objectives The Middle East and North Africa (MENA)
region is perceived to have limited HIV data. The
objective of this study was to quantitatively characterise
the progress in HIV research in this region since the
discovery of the epidemic.
Methods Four indices were deﬁned and implemented
to measure the progress of HIV research using the
PubMed, Embase, MENA HIV/AIDS Epidemiology
Synthesis Project and US Census Bureau HIV/AIDS
Surveillance databases. The four indices provide
complementary measures to characterise different
aspects of the progress of HIV research.
Results A total of 2118, 2352, 683 and 4889 records
were identiﬁed through the PubMed, the Embase, the
Synthesis Project and the HIV Prevalence indices,
respectively. The proportion of the total global HIV
records that relate to MENA is 1.2%. Overall, the indices
show steady progress in the number of new records
every year, with an accelerated pace in the last few
years. The rate of progress in MENA was also higher
than the rate of progress in HIV records globally. There is
no evidence so far of stabilisation or a peak in the
number of new records year by year. About half of the
records were produced after the year 2005. The number
of records shows large heterogeneity across countries.
Conclusions MENA has witnessed a rapid growth in
HIV research over the last decade. However, there are
still large gaps in HIV scientiﬁc evidence in the region,
and the progress is far from being uniform across
countries. Ongoing and future research needs to be
geared towards academic standard and production of
scientiﬁc publications.
INTRODUCTION
The Middle East and North Africa (MENA) region
is viewed as the anomaly in the HIV/AIDS world
map and ‘a real hole in terms of HIV/AIDS epi-
demiological data’.1 The region is also perceived
to have failed to address the HIV public-health
challenge, and in denial of the reality of the HIV
epidemic in this part of the world.2 3 The aim of
this article is to document and quantitatively char-
acterise the growth in HIV research in MENA over
the last three decades since the discovery of the
epidemic.
METHODOLOGY
We deﬁned and implemented four indices for meas-
uring the progress of HIV research in MENA.
These correspond to the number of publications or
data retrieved through a search of four different
sources of data. The indices are as follows:
▸ PubMed Index: The number of records identi-
ﬁed through a search of studies on HIV in
MENA in PubMed (Medline) database using a
strategy with both free text and MeSH head-
ings, and with no language or year restrictions.
MeSH headings were exploded to cover all sub-
headings. The cut-off date for our search was 9
October 2012. The search criteria can be found
in box 1.
▸ Embase Index: The number of records identi-
ﬁed through a comprehensive search of
studies on HIV in MENA in Embase database
using a strategy with both free text and
Emtree terms, and with no language or year
restrictions. Emtree terms were exploded to
cover all subheadings. The cut-off date for
our search was 9 October 2012. The search
criteria can be found in box 1.
▸ MENA HIV/AIDS Epidemiology Synthesis
Project Index: The number of records that are
not part of either the PubMed or the Embase
databases, but are part of the MENA HIV/AIDS
Epidemiology Synthesis Project EndNote data-
base.4 These records include predominantly
country-level or international organisation
reports, all of which have not been published in
the scientiﬁc literature. These documents were
obtained through our network formed by
working with the countries and different
national and international organisations in this
region. These documents were compiled indi-
vidually based on their actual relevance to HIV
in MENA.
▸ HIV Prevalence Index: The number of HIV
point-prevalence surveys as extracted from
the US Census Bureau HIV/AIDS Surveillance
database,5 a comprehensive compilation of
global HIV prevalence measures irrespective
of collection methodology. The cut-off date
for inclusion was 9 October 2012. The
numbers quoted for Sudan includes both
Sudan and the newly formed Republic of
South Sudan.
The four indices capture different aspects of the
progress of HIV research in MENA, and each one
complements or corrects for potential biases in
the other indices. While the PubMed and Embase
indices characterise the progress in terms of pub-
lished HIV research in the scientiﬁc literature, the
Synthesis Project Index characterises the progress in
the unpublished grey literature. This is essential as
a large volume of HIV studies in MENA have
never been published in scientiﬁc journals due to
multiple obstacles.4 6 Although both the PubMed
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and Embase indices focus on the published literature, there are
differences in the sources of literature that are indexed in each
of these databases. Embase has also the advantage of including
additional sources of data that appeared only in conference
abstracts. Similarly, while the ﬁrst three indices cover a wide
range of HIV-related studies including biological, behavioural
and other contextual studies, the HIV Prevalence Index strictly
measures the progress of HIV research in producing objective
biomarkers of the level of HIV infection in various population
groups.
Lastly, we compared the contribution of MENA to the total
global HIV research output using the PubMed Index to quantify
the magnitude and trend of MENA contribution relative to the
global contribution. The search criteria for the global HIV
research search can be found in box 1.
RESULTS
We identiﬁed a total number of 2118 records through the
PubMed Index, 2352 records through the Embase Index, 683
records through the Synthesis Project Index and 4889 records
through the HIV Prevalence Index. The year-by-year distribution
of each of these indices can be seen in ﬁgure 1. Overall, the
indices collectively show steady increase in the number of new
records every year, with an accelerated growth during the last
few years. While still small, the fraction of MENA HIV records
in PubMed, relative to global HIV records, has steadily increased
from insigniﬁcant levels in earlier years to 1.2% in 2011
(ﬁgure 2A). More than half of the MENA records were produced
only in the last few years, around 2005 and subsequent years.
Records on HIV in MENA started to appear in the mid-1980s,
but at a slow rate. There is no evidence so far of stabilisation or a
peak in the number of new records year by year, suggesting that
HIV research continues to be in an expansion phase.
Figure 2B shows the distribution of studies by country
through the HIV Prevalence Index. The number of records per
country shows large heterogeneity with few countries producing
hundreds of prevalence measures, while others having few avail-
able measures. Morocco, for example, has the highest number
of records at 1089, while only one prevalence measure was
found for the United Arab Emirates.
DISCUSSION
The contribution of MENA to the global HIV literature is still
meagre at just over 1%, though MENA’s population comprises
nearly 10% of the world’s population. Nevertheless, the results
of our study indicate that MENA has witnessed a rapid growth
in HIV research over the last decade. The results were consistent
on this conclusion regardless of the index used to measure the
progress. The pace of growth continues and at a faster rate com-
pared to the global literature (ﬁgure 2A). The widely held per-
ceptions of limited HIV data in MENA, if not inaccurate,
exaggerate the limitations of our epidemic knowledge in this
region. Though there are still large gaps in HIV evidence, these
should not prevent us from appreciating what has been achieved
in just a few years over the last decade.
This advancement in the quantity of studies masks a remark-
able progress in the quality of studies, which has greatly
improved over the last few years. Studies in earlier years
tended to have methodological limitations, were mostly
descriptive or qualitative in nature and were conducted on con-
venience samples that are not necessarily representative, such as
facility-based or venue-based samples.4 6–8 However, the region
has witnessed recently a clear shift in the nature of evidence
with multiple studies being conducted with state-of-the-art
research methodologies (further discussion of study quality
can be found in4 6–8). An example of quality studies are
the integrated bio-behavioural surveillance surveys using
innovative sampling methodologies for hard to reach popula-
tions such as respondent-driven sampling. Some countries such
as Afghanistan, Egypt, Iran, Pakistan and Tunisia have now
several rounds of surveillance among high-risk populations pro-
viding longitudinal data to track the evolution of the epi-
demic.9 Other countries have conducted their ﬁrst round of
surveillance; and in most of these, subsequent rounds are
either planned or being implemented.7–9 All in all, the last
decade in MENA can be described as a ‘brave new world’ in
HIV research, after years in which the mere recognition that
Box 1 Details of the search criteria used to search
PubMed and Embase databases for relevant articles
PubMed Index Search Criteria
1. HIV in Middle East and North Africa (MENA) search
(‘HIV’[Mesh] OR ‘HIV Seropositivity’[Mesh] OR ‘HIV
Antibodies’[Mesh] OR ‘HIV Infections’[Mesh] OR ‘HIV
Seroprevalence’[Mesh] OR HIV [Text] or ‘Human
immunodeﬁciency virus’[Text]) AND (‘Middle East’[Mesh] OR
‘Islam’[Mesh] OR ‘Arabs’[Mesh] OR ‘Arab World’[Mesh] OR
‘Africa, Northern’[Mesh] OR ‘Sudan’[Mesh] OR ‘Somalia’[Mesh]
OR ‘Djibouti’[Mesh] OR ‘Pakistan’[Mesh] OR ‘Middle East’[Text] OR
‘Middle-East’[Text] OR ‘North Africa’[Text] OR ‘North-Africa’[Text] OR
‘EMRO’[Text] OR ‘Eastern Mediterranean’[Text] OR ‘Arab’[Text] OR
‘Arabs’[Text] OR ‘Arab World’[Text] OR ‘Islam’[Text] OR
‘Afghanistan’[Text] OR ‘Algeria’[Text] OR ‘Bahrain’[Text] OR
‘Djibouti’[Text] OR ‘Egypt’[Text] OR ‘Jordan’[Text] OR ‘Kuwait’[Text]
OR ‘Lebanon’[Text] OR ‘Libya’[Text] OR ‘Iran’ [Text] OR ‘Iraq’[Text]
OR ‘Morocco’[Text] OR ‘Oman’[Text] OR ‘Pakistan’[Text] OR
‘Qatar’[Text] OR ‘Saudi Arabia’[Text] OR ‘Somalia’[Text] OR
‘Sudan’[Text] OR ‘Syria’[Text] OR ‘Tunisia’[Text] OR ‘United Arab
Emirates’[Text] OR ‘Dubai’[Text] OR ‘Abu Dhabi’[Text] OR
‘Abu-Dhabi’[Text] OR ‘Sharjah’[Text] OR ‘West Bank’[Text] OR
‘Ghaza’[Text] OR ‘Palestine’[Text] OR‘Yemen’[Text]).
2. Global HIV search
‘HIV’[Mesh] OR ‘HIV Seropositivity’[Mesh] OR ‘HIV
Antibodies’[Mesh] OR ‘HIV Infections’[Mesh] OR ‘HIV
Seroprevalence’[Mesh] OR HIV [Text] or ‘Human
immunodeﬁciency virus’[Text]
Embase Index Search Criteria
1. HIV in MENA search
(exp Human immunodeﬁciency virus/ or HIV.mp. or Human
immunodeﬁciency virus.mp.) AND (exp Middle East/ or exp North
Africa/ or exp Arab/ or exp Afghanistan/ or exp Djibouti/ or exp
Pakistan/ or exp Somalia/ or exp Sudan/ or Middle East.mp. or
North Africa.mp. or EMRO.mp. or Eastern Mediterranean.mp. or
Arab.mp. or Arabs.mp. or Arab World.mp. or Islam.mp. or
Afghanistan.mp. or Algeria.mp. or Bahrain.mp. or Djibouti.mp. or
Egypt.mp. or Jordan.mp. or Kuwait.mp. or Lebanon.mp. or Libya.
mp. or Iran.mp. or Iraq.mp. or Morocco.mp. or Oman.mp. or
Pakistan.mp. or Qatar.mp. or Saudi Arabia.mp. or Somalia.mp. or
Sudan.mp. or Syria.mp. or Tunisia.mp. or United Arab Emirates.
mp. or Dubai.mp. or Abu Dhabi.mp. or Sharjah.mp. or West Bank.
mp. or Ghaza.mp. or Palestine.mp. or Yemen.mp).
2. Global HIV search
exp Human immunodeﬁciency virus/ or HIV.mp. or Human
immunodeﬁciency virus.mp.
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HIV is present and circulating in MENA countries was a
taboo.4 10 11 It is not known, however, whether the ongoing
global ﬁnancial crisis, and the regional political instability, may
impede this progress.
This progress, nevertheless, was not uniform across MENA
countries. The last decade is marked by a widening disparity in
HIV efforts (ﬁgure 2B). While few countries have made impres-
sive strides, other countries continue to be far behind in terms of
their will and capacity to conduct HIV research. Ironically, HIV
research output does not appear to correlate with the country’s
per capita income. The Arabian Gulf countries that have the
highest per capita income in the region have contributed minim-
ally to this progress. Meanwhile, countries with constrained
ﬁnancial resources have made sizable contributions. In part, this
reﬂects the fact that limited resource countries in the region,
whenever they had strong commitment to advance HIV research,
had access to funds through international donors such as the
Global Fund to Fight AIDS, Tuberculosis and Malaria.12 This
external support did not only provide Financial Resources to
conduct studies, but most often contributed to capacity building
within the countries through collaborative partnerships with
international organisations working in the region, or through
involvement of international consultants or experts.12
Morocco provides a notable example in this regards. Thanks to
strong national commitment, and despite the limited resources,
Morocco established surveillance systems with a national reach,
submitted quality applications to the Global Fund that succeeded
in securing ﬁnancial and technical support and facilitated an envir-
onment for the civil society and non-governmental organisations
to play an important role in HIVefforts.13 14
The Synthesis Project Index provides an indication of how a
large volume of research in MENA never reaches the stage of
Figure 1 Progress of HIV research in the Middle East and North Africa (MENA) region since the discovery of the HIV epidemic. (A) Number of HIV
records using the PubMed Index. (B) Number of HIV records using the Embase Index. (C) Number of HIV records using the MENA HIV/AIDS
Epidemiology Synthesis Project Index. (D) Number of HIV point-prevalence surveys using the HIV Prevalence Index. Access the article online to view
this ﬁgure in colour.
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publication in scientiﬁc journals (ﬁgure 1). This is a structural
weakness that reﬂects multiple factors, one of which is probably
insufﬁcient interest in academic publications. Many of the
studies are conduced or supported through national pro-
grammes with limited interest in using the data beyond inform-
ing HIV policy and programmes at the national level.4 6
Limitations in the capacity to draft scientiﬁc publications, issues
related to ownership of data and political sensitivity of the ﬁnd-
ings of some of the studies, may have further strained the
efforts towards publication and dissemination to a wider
audience.
Each of the four indices has its own limitations in capturing
the diverse aspects that characterise the progress of HIV
research in MENA. Some of the limitations in any speciﬁc index
are addressed by the strengths of the other indices. However,
this is not necessarily true for all limitations. For example, the
total number of citations retrieved through PubMed and
Embase is only a proxy of the number of publications that actu-
ally have primary data on HIV in the region. Nonetheless,
screening of these two searches as part of previous systematic
reviews conducted by the authors6–8 13 15 16 conﬁrmed a strong
correlation between the total number of citations retrieved and
the number of citations with actual data, with substantially more
data being published in recent years.
Another limitation in our study is that the active systematic
phase of the Synthesis Project to collect non-published HIV
literature has ended in early 2009; a fact reﬂected in the drop in
the number of records through this index after 2008. The
drop accordingly does not reﬂect a true reduction in the
number of new records of unpublished literature, as much as it
is an artefact of the Synthesis Project process. Similarly, the drop
in the HIV Prevalence Index after 2008 appears to reﬂect limita-
tions in reporting to or updating the US Census Bureau HIV/
AIDS Surveillance database with new data entries in the last few
years.
In conclusion, MENA has been witnessing a rapid growth in
HIV research in the last few years despite signiﬁcant challenges.
Nevertheless, the region’s contribution to global literature
remains small relative to its population size and actual needs.
There are knowledge gaps waiting to be ﬁlled, and the overall
quality of studies still needs to be improved. Ongoing research
efforts should be supported in a sustainable fashion to ensure
the durability of the progress. Research should be conducted up
to academic standard leading to scientiﬁc publications.
Countries lagging in terms of research output should vigorously
expand their research efforts to address the emerging HIV epi-
demics in this region.6 7 15 Surveillance systems and research
studies should be geared primarily towards high-risk populations
Figure 2 (A) Fraction of the Middle East and North Africa (MENA) HIV records in PubMed relative to global HIV records. (B) Distribution of HIV
point-prevalence measures per country using the HIV Prevalence Index. Access the article online to view this ﬁgure in colour.
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who are most affected by the epidemic. Integrated bio-
behavioural surveillance surveys among these populations need
to be conducted and repeated every few years. Risk-group size
estimations, mapping and ethnographic studies and a better
understanding of the sexual and injecting networks are war-
ranted. General population sexual behaviour surveys will add
useful data on the proﬁle of risk behaviour in the population at
large. Studies on HIV infected persons to improve case manage-
ment are required. All of such studies are not only important
for their direct beneﬁts, but also important indirectly by facili-
tating and powering mathematical modelling and cost-
effectiveness analyses.
Key messages
▸ The Middle East and North Africa region has witnessed an
impressive rapid growth in HIV research over the last
decade.
▸ HIV research progress is heterogeneous across the countries
of the region, and research output varies substantially from
one country to another.
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